Diagnostic utility of serum adenosine deaminase level in the diagnosis of pulmonary tuberculosis
Abdelsadek H. Alaarag\textsuperscript{a}, Osama I. Mohammad\textsuperscript{a}, Naglaa M. Farag\textsuperscript{b}

\textbf{Aim of the work} This study was conducted to evaluate the role of serum adenosine deaminase (ADA) level in the diagnosis of pulmonary tuberculosis (TB) and its relationship with clinical, radiological, and laboratory parameters.

\textbf{Patients and methods} This study was performed on 70 individuals: 60 patients with tuberculous and nontuberculous pulmonary diseases and 10 apparently healthy individuals as a control group. The participants were divided into four groups: group I included 30 patients with active pulmonary TB who were subdivided into group IA, which included 20 patients with sputum smear-positive pulmonary TB, and group IB, which included 10 patients with sputum smear-negative pulmonary TB (culture positive); group II included 10 patients with tuberculous pleural effusion; group III included 20 patients with nontuberculous lung diseases (five cases with pneumonia, five cases with pyogenic lung abscess, five cases with bronchiectasis, three cases with lung cancer, and two cases with mesothelioma); and group IV included 10 apparently healthy individuals as a control group. Patients were subjected to history taking, clinical examination, plain chest radiography posterior–anterior view, three consecutive sputum smears for acid-fast bacilli (AFB), sputum culture for AFB using BACTEC TB-460 system in group IB, laboratory investigations, tuberculin skin test, serum ADA level evaluation in all participants, and pleural ADA level evaluation in cases of tuberculous pleural effusion.

\textbf{Introduction} Tuberculosis (TB) is an infectious bacterial disease caused by \textit{Mycobacterium tuberculosis}, which most commonly affects the lungs. It is transmitted from person to person through droplets from the throat and lungs of people with the active respiratory disease. In healthy people, infection with \textit{M. tuberculosis} often causes no symptoms, as the person’s immune system acts to ‘wall off’ the bacteria. The symptoms of active TB of the lung are coughing, sometimes with sputum or blood, chest pain, weakness, weight loss, fever, and night sweats. TB is treatable with a 6-month course of antibiotics [1]. A positive acid-fast bacilli (AFB) smear and/or culture of \textit{Mycobacterium} spp. is the gold standard for the diagnosis of TB. Although smear positivity correlates well with infectivity, much of the transmission occurs before the level of bacilli reach 10 000/ml in the sputum. Infection is a sophisticated process and certainly occurs from paucibacillary and smear-negative cases, which are more common in HIV seropositives [2]. Chest radiograph provides only a probable diagnosis; they are sometimes difficult to differentiate from other causes of lung shadows, such as pneumonia and malignancies [3].

\textbf{Results} Serum ADA showed high percentage positivity (90%) in the diagnosis of pulmonary TB, followed by tuberculin skin test (83.3%), chest radiography (73.3%), erythrocyte sedimentation rate (70%), sputum for AFB (66.6%), toxic symptoms (53.3%), and hemoptysis (36.3%). Serum ADA sensitivity and specificity at cut-off point 30.15 μl/l were 95 and 86.7%, respectively, with a positive predictive value of 90.5%, negative predictive value of 92.2%, and accuracy of 91.4%.

\textbf{Conclusion} Serum ADA level shows higher percentage positivity compared with clinical, radiological, and laboratory parameters in the diagnosis of pulmonary TB.

This study was performed on 70 patients with tuberculous and nontuberculous pulmonary diseases and 10 apparently healthy individuals as a control group. The participants were divided into four groups: group I included 30 patients with active pulmonary TB who were subdivided into group IA, which included 20 patients with sputum smear-positive pulmonary TB, and group IB, which included 10 patients with sputum smear-negative pulmonary TB (culture positive); group II included 10 patients with tuberculous pleural effusion; group III included 20 patients with nontuberculous lung diseases (five cases with pneumonia, five cases with pyogenic lung abscess, five cases with bronchiectasis, three cases with lung cancer, and two cases with mesothelioma); and group IV included 10 apparently healthy individuals as a control group. Patients were subjected to history taking, clinical examination, plain chest radiography posterior–anterior view, three consecutive sputum smears for acid-fast bacilli (AFB), sputum culture for AFB using BACTEC TB-460 system in group IB, laboratory investigations, tuberculin skin test, serum ADA level evaluation in all participants, and pleural ADA level evaluation in cases of tuberculous pleural effusion.

\textbf{Erythrocyte sedimentation rate (ESR)} is a nonspecific investigation, which may become rapid in a large variety of clinical conditions ranging from anemia to any chronic infectious, inflammatory, or malignant disease. ESR has absolutely no diagnostic value for TB diagnosis as a standalone criterion. However, in conjunction with other clinical parameters, its raised value can indicate a possibility of TB [2]. Adenosine deaminase (ADA) is an enzyme of purine. It is needed for the breakdown of adenosine from food and for the turnover of nucleic acids in tissues. Moreover, it regulates lymphocyte metabolism and is important for lymphocytic differentiation and growth. It is present in lymphocytes in high concentration [4]. Its activity appears to be necessary for an effective immune response as shown by many studies, such as in combined immunodeficiency disease and in typhoid fever. Besides this, increased activity of \textit{Mycobacterium} spp. is the gold standard for the diagnosis of TB. Although smear positivity correlates well with infectivity, much of the transmission occurs before the level of bacilli reach 10 000/ml in the sputum. Infection is a sophisticated process and certainly occurs from paucibacillary and smear-negative cases, which are more common in HIV seropositives [2]. Chest radiograph provides only a probable diagnosis; they are sometimes difficult to differentiate from other causes of lung shadows, such as pneumonia and malignancies [3].

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work noncommercially, as long as the author is credited and the new creations are licensed under the identical terms.
serum ADA has also been demonstrated in tuberculous pleural effusion, peritoneal TB, AIDS, and cancer [5].

**Patients and methods**

This prospective study was performed on 70 individuals: 60 patients who were admitted in the Chest Department Benha University Hospitals and Abbassia Chest Hospital during the period between October 2012 and October 2013 and 10 apparently healthy individuals who served as a control group. The study gained approval of local ethical committee of chest department, Benha University. The participants were divided into four groups. Group I included 30 patients with active pulmonary TB. Their ages ranged from 13 to 65 years, with a mean age of 37.6 years. There were 26 male and four female patients. This group was further subdivided into two groups: group IA included 20 patients with sputum smear-positive pulmonary TB, and group IB included 10 patients with sputum smear-negative culture-positive pulmonary TB. Group II included 10 patients with tuberculous pleural effusion, eight male and two female. Their ages ranged from 18 to 55 years, with a mean age of 35 years. Group III included 20 patients with nontuberculous lung diseases. Their ages ranged from 20 to 76 years, with a mean age of 52.35 years. This group included five patients diagnosed with pneumonia, five patients diagnosed with pyogenic lung abscess, five patients diagnosed with bronchiectasis, three patients diagnosed with lung cancer, and two patients diagnosed with mesothelioma. Group IV included 10 apparently healthy individuals as a control group, six male and four female. Their ages ranged from 26 to 57 years, with a mean age of 36.1 years.

Inclusion criteria for group I: group Ia – sputum smear-positive pulmonary TB: (a) two or more initial sputum smear examinations positive for AFB, and (b) one sputum smear examination positive for AFB + radiographic abnormalities consistent with active pulmonary TB [6]. Group Ib – sputum smear-negative pulmonary TB: (a) two sets (taken at least 2 weeks apart) of at least two sputum specimens negative for AFB; radiographic abnormalities consistent with active pulmonary TB; lack of clinical response despite a full course of broad spectrum antibiotic administration; a decision by physician to treat with a full course of anti-TB chemotherapy; and (b) sputum-negative culture-positive for *M. tuberculosis* [6].

Inclusion criteria for group II: cytological examination of pleural fluid that was highly rich in lymphocytes and confirmed by means of pleural biopsy that revealed caseating granuloma [7].

Exclusion criteria for group I: extrapulmonary TB, diabetes mellitus, being on corticosteroids, presence of hepatic or renal impairment, and being on antituberculous treatment.

Patients were subjected to the following:

Full history taking, full clinical examination, plain chest radiography posterior–anterior view, three consecutive sputum smears for AFB, sputum culture for AFB using BACTEC TB-460 (Becton Dickinson, Sparks, MD, USA) system in group IB [8], laboratory investigations (complete blood count, ESR, fasting blood sugar, serum glutamic oxaloacetic transaminase, serum glutamic oxaloacetic transaminase, serum urea, and creatinine), tuberculin skin test using the Mantoux technique [9], serum ADA evaluation, and pleural ADA level in group II. ADA estimation was carried out using the sensitive colorimetric method described by Guisti and Galanti [10] with BIOSIC kit cod ADAo16 (Diazyme General Atomics, California, USA). Other investigations that were carried out for the diagnosis of individual cases were as follows: CT of the chest for 13 cases, CT-guided biopsy for two cases, bronchoscope for one case, Abram’s needle biopsy for one case, open pleural biopsy for one case, and medical thoracoscopy in 10 cases.

**Data management and analysis**

The collected data were revised, coded, tabulated, and introduced into a PC using statistical package for social science (15.0.1 for Windows, 2001; SPSS Inc., Chicago, Illinois, USA).

**Results**

For results, see Tables 1–9. There was no statistical significant difference between the studied groups as regarding to sex distribution. Regarding to age there was a highly statistical significant difference between group I and group III, on the other hand there is no statistical significant difference between group I and both groups II and IV. The most prominent presenting symptoms in group I were cough and expectoration in 100% of them, in group II the most prominent presenting symptoms were cough and dyspnea in 100% of patients. While in group III cough is the most prominent presenting symptom in 100% of patients followed by expectoration in 90% and dyspnea in 85% of them. There was no statistical significant difference between group IA and both groups IB and group II as regarding to serum ADA.
On the other hand there was a highly statistical significant difference between group IA and both groups III and IV as regarding to serum ADA. Regarding also to serum ADA there was no statistical significant difference between group IB and group II, on the other hand there was a highly statistical significant difference between group IB and both groups III and IV as regarding to serum ADA. There was a highly statistical significant difference between group II and both groups III and IV as regarding to serum ADA. Ratio of ADA activity in the pleural fluid to serum in group II was 2.3:1. The best cut-off value obtained from the ROC (receiver operator characteristic) curve method for serum ADA is 30.15. At this point sensitivity was 95% and specificity 86.7% with positive predictive value (PPV) 90.5%, negative predictive value (NPV) 92.9% and accuracy is 91.4%. Serum ADA shows high percent positivity 90% followed by tuberculin skin test 83.3%, chest x-ray 73.3%, ESR 70%, sputum AFB 66.6%, toxic symptoms 53.3% and hemoptysis 36.3%.

**Discussion**

TB continues to be a major cause of morbidity and mortality worldwide. The diagnosis is usually based on clinical presentation, radiographic findings, and positive tuberculin test. However, clinical and radiographic features are variable and the latter test may be falsely negative. Under such circumstances, antituberculous therapy is started empirically. It therefore becomes imperative to find some rapid and useful tests for the diagnosis of TB [11]. ADA is an enzyme that catalyzes the hydrolytic and irreversible deamination of adenosine to inosine, as well as deoxyadenosine to deoxynosine. The determination of ADA concentration in pleural fluid is currently used

### Table 1 Statistical analysis between the studied groups as regards sex

| Sex       | Group I [n (%)] | Group II [n (%)] | Group III [n (%)] | Group IV [n (%)] | Total [n (%)] |
|-----------|-----------------|------------------|-------------------|-----------------|---------------|
| Male      | 26 (86.7)       | 8 (80.0)         | 16 (80.0)         | 6 (60)          | 56 (80)       |
| Female    | 4 (13.3)        | 2 (20.0)         | 4 (20.0)          | 4 (40)          | 14 (20)       |
| Total     | 30 (100)        | 10 (100)         | 20 (100)          | 10 (100)        | 70 (100)      |

**P**

- **P**<sub>1</sub> = group I vs. group II: **P**<sub>1</sub> > 0.05 (NS)
- **P**<sub>2</sub> = group I vs. group III: **P**<sub>2</sub> > 0.05 (NS)
- **P**<sub>3</sub> = group I vs. group IV: **P**<sub>3</sub> > 0.05 (NS)

There was no statistically significant difference between the studied groups as regards sex distribution. NS, nonsignificant.

### Table 2 Statistical analysis between the studied groups as regards age

| Age        | Group I | Group II | Group III | Group IV | Total |
|------------|---------|----------|-----------|----------|-------|
| Range      | 13–65   | 18–55    | 20–76     | 26–57    |       |
| Mean±SD    | 37.6±14.87 | 35.0±11.29 | 52.35±15.48 | 36.1±11.97 |       |

**P**

- **P**<sub>1</sub> = group I vs. group II: **P**<sub>1</sub> > 0.05 (NS)
- **P**<sub>2</sub> = group I vs. group III: **P**<sub>2</sub> < 0.01 (HS)
- **P**<sub>3</sub> = group I vs. group IV: **P**<sub>3</sub> > 0.05 (NS)

There was a highly statistically significant difference between groups I and III as regards age. However, there was no statistically significant difference between group I and both groups II and IV as regards age. HS, highly significant; NS, nonsignificant.

### Table 3 Statistical comparison between the studied groups as regards presenting symptoms

| Variables      | Group I [N=30] [n (%)] | Group II [N=10] [n (%)] | Group III [N=20] [n (%)] | Group IV [N=10] [n (%)] | Total [N=70] [n (%)] |
|----------------|------------------------|-------------------------|--------------------------|-------------------------|---------------------|
| Cough          | 30 (100)               | 10 (100)                | 20 (100)                 | 0 (0.0)                 | 60 (85.7)           |
| Expectoration  | 30 (100)               | 2 (20)                  | 18 (90)                  | 0 (0.0)                 | 50 (71.4)           |
| Dyspnea        | 21 (70)                | 10 (100)                | 17 (85)                  | 0 (0.0)                 | 48 (68.6)           |
| Hemoptysis     | 11 (36.7)              | 6 (30)                  | 2 (10)                   | 0 (0.0)                 | 17 (24.3)           |
| Toxemia        | 16 (53.3)              | 3 (30)                  | 4 (20)                   | 0 (0.0)                 | 23 (32.9)           |
| Chest pain     | 9 (30)                 | 5 (50)                  | 12 (60)                  | 0 (0.0)                 | 26 (37.1)           |

The most prominent presenting symptoms in group I were cough and expectoration in 100% of them. In group II, the most prominent presenting symptoms were cough and dyspnea in 100% of patients. In group III, cough was the most prominent presenting symptom in 100% of patients, followed by expectoration in 90% and dyspnea in 85% of them.
for the diagnosis of tuberculous pleurisy. There are also studies showing high levels of ADA in serum and bronchoalveolar lavage (BAL) of patients with pulmonary TB [12]. As regards the presenting symptoms in the studied groups (Table 3), the most prevalent complaint was cough, as it was found in all 60 (100%) patients, followed by expectoration in 50 (83.3%) patients, dyspnea in 48 (80%) patients, chest pain in 29 (43.3%), toxic manifestations in 23 (38.3%) patients, and hemoptysis in 19 (28.3%) patients. This result is in accordance with that of Hassanein and colleagues, who studied the role of ADA in the diagnosis of pulmonary TB. Their study included 50 individuals: 20 patients with sputum positive for AFB, 10 patients with bronchogenic carcinoma, 10 patients with pneumonia, and 10 normal healthy individuals. The study showed that the most prevalent complaint among the 50 individuals was cough in all 80 (100%) patients, followed by expectoration in 31 (62%) patients, hemoptysis in 16 (32%) patients, chest pain in 15 (30%) patients, and toxic manifestations in 14 (28%) patients. This indicates that cough is the most common symptom in all chest diseases and is the most common symptom that brings the patients to physicians to seek medical advice [13]. In this study, the ADA level in the studied groups was as follows (Tables 4–6): ADA level in group IA ranged from 29 to 48.5 μ/l, with a mean of 36.97±4.92; in group IB it ranged from 30.1 to 62 μ/l, with a mean of 39.89±9.56; in group II it ranged from 30.4 to 37 μ/l, with a mean of 34.03±2.12; in group III it ranged from 12.4 to 30.2 μ/l, with a mean of 22.13±4.39; and in group IV it ranged from 7 to 20 μ/l, with a mean of 14.99±4.50. There was a highly statistically significant difference between group I (IA and IB) and both groups III and IV as regards serum ADA. (P<0.01) as regards the level of serum ADA. There was also a highly statistically significant difference between group I (IA and IB) and both groups III and IV (P<0.01) as regards the level of serum ADA. There was also a highly statistically significant difference between group II and both groups III and IV with regard to serum ADA. However, there was a highly statistically significant difference between group IB and both groups III and IV with regard to serum ADA, ADA, adenosine deaminase; HS, highly significant; NS, nonsignificant.

Table 4 Comparison between group IA versus other groups as regards serum ADA

| Variables | Serum ADA (U/l) | Mean±SD | t  | P   |
|-----------|----------------|---------|----|-----|
| Group IA  | 29–48.5        | 36.97±4.92 | –  | –   |
| Group IB  | 30.1–62        | 39.89±9.56 | 1.114 | 0.275 (NS) |
| Group II  | 30.4–37        | 34.03±2.12 | 1.8 | 0.083 (NS) |
| Group III | 12.4–30.2      | 22.13±4.39 | 10.07 | 0.001 (HS) |
| Group IV  | 7–20           | 14.99±4.5 | 11.85 | 0.001 (HS) |

There was no statistically significant difference between group IA and both groups IB and II as regards serum ADA. In contrast, there was a highly statistically significant difference between group IA and both groups III and IV as regards serum ADA. However, there was a highly statistically significant difference between group IB and both groups III and IV as regards serum ADA.

Table 5 Comparison between groups IB versus other groups as regard serum ADA

| Variables | Serum ADA (U/l) | Mean±SD | t  | P   |
|-----------|----------------|---------|----|-----|
| Group IB  | 30.1–62        | 39.89±9.56 | –  | –   |
| Group II  | 30.4–37        | 34.03±2.12 | 1.89 | 0.075 (NS) |
| Group III | 12.4–30.2      | 22.13±4.39 | 7.04 | 0.001 (HS) |
| Group IV  | 7–20           | 14.99±4.5 | 7.45 | 0.001 (HS) |

There was no statistically significant difference between groups IB and II as regards serum ADA. However, there was a highly statistically significant difference between group IB and both groups III and IV with regard to serum ADA. ADA, adenosine deaminase; HS, highly significant; NS, nonsignificant.

Table 6 Comparison between group II versus other groups as regard serum ADA

| Variables | Serum ADA (U/l) | Mean±SD | t  | P   |
|-----------|----------------|---------|----|-----|
| Group II  | 30.4–37        | 34.03±2.12 | –  | –   |
| Group III | 12.4–30.2      | 22.13±4.39 | 8.06 | 0.001 (HS) |
| Group IV  | 7–20           | 14.99±4.5 | 12.1 | 0.001 (HS) |

There was a highly statistically significant difference between group II and both groups III and IV as regards serum ADA. ADA, adenosine deaminase; HS, highly significant.

Table 7 ADA activity in pleural fluid and the serum in group II

| Pleural fluid ADA | Serum ADA | Ratio |
|-------------------|-----------|-------|
| Range             | 56–120    | 30.4–37 |       |
| Mean±SD           | 79.1±19.81| 34.03±2.12| 2.3 : 1 |

The ratio of ADA activity in the pleural fluid to serum in group II was 2.3 : 1. ADA, adenosine deaminase; TB, tuberculous pleural.
Similar results were obtained by Hassanein et al. [14], who assessed the role of ADA in serum and BAL fluid in the diagnosis of pulmonary TB and proved that patients with pulmonary TB had significantly higher ADA level in serum and BAL fluid compared with patients with nontuberculous lung diseases (lung cancer and pneumonia) and normal individuals. The results of the present study are also in accordance with those of Rao and colleagues, who studied the value of serum ADA activity in the diagnosis of pulmonary TB in India. They conducted the study on 142 cases and found that the mean ADA in TB patients was 40.48 and 41.3 μ/l in TB pleural effusion, whereas it was 28.4 μ/l in patients with nontuberculous chest diseases and 17.4 μ/l in the healthy group. The authors in their study stated that, as the determination of ADA is not costly or time consuming, it should be performed routinely, particularly if the diagnosis is in doubt, clinically suggestive but sputum AFB-negative, as well as to differentiate pulmonary TB from nontuberculous pulmonary diseases [7].

The results of the present study are also in agreement with those of Chander and Shrestha, who studied the diagnostic value of serum ADA level in sputum smear-negative pulmonary TB patients in Nepalese population. The study was conducted on 262 cases that were divided into three groups: group I included 142 cases of sputum smear-negative pulmonary TB with a mean ADA level of 42.26±21.22 μ/l; group II included 40 cases of COPD with a mean ADA level of 23.31±8.22 μ/l; and group III included 88 individuals as a healthy control group with a mean ADA level of 18.88±6.67 μ/l. Their results showed high statistically significant difference between group I and both groups II and III. They stressed that the overall assessment of the uses of serum ADA levels as a diagnostic biochemical marker in smear-negative pulmonary TB patients showed promising results. Our study and all previous studies confirm the importance of ADA as a diagnostic tool in all forms of TB, pulmonary (smear positive and smear negative) and extrapulmonary as in tuberculosis pleural effusion [15]. Increased serum ADA levels in pulmonary TB may be due to the stimulation of cell-mediated immunity. A fully functioning cell-mediated immune response is dependent on normal lymphocyte metabolism, which in part is regulated by the purine salvage enzyme ADA [16]. In a study by Conde and colleagues, the serum ADA levels decreased to normal levels after 1 month of the initiation of effective treatment in patients with pulmonary TB. They suggested that the decrease in serum ADA levels could be due to the normalization of altered lymphocytes turnover induced by TB [17]. Thora et al. [18] showed the raised activity of ADA in the newborn sera, 6 weeks after Bacillus Calmette–Guérin (BCG) vaccination. Alatas and colleagues determined the role of serum ADA activity in the diagnosis and follow up of pulmonary TB and monitoring the efficiency of therapy. A significant difference was observed in ADA activity before and after treatment, also from old TB patients and healthy controls. They stated that ADA activity is increased in pulmonary TB patients, which is a helpful parameter for monitoring therapy [19]. As shown in Table 7, ADA activity in pleural fluid and the serum in group II was evaluated. ADA level in pleural effusion ranged from 56 to 120 μ/l with a mean of 79.1±19.8, and serum ADA ranged from 30.4 to 37 μ/l with a mean of 34.03±2.12. The ratio of pleural fluid ADA compared with serum ADA was 2.3:1. This means that the level of pleural fluid ADA was significantly higher than that of serum ADA level; this is due to localized intrapleural production of ADA from increased

### Table 8 Sensitivity specificity, PPV, NPV, and accuracy of serum ADA in the diagnosis of tuberculosis

| Variables       | %       |
|-----------------|---------|
| AUC             | 0.998   |
| Best cut-off value | 30.15  |
| Sensitivity     | 95      |
| Specificity     | 86.7    |
| PPV             | 90.5    |
| NPV             | 92.9    |
| Accuracy        | 91.4    |

The best cut-off value obtained from the receiver operator characteristic curve method for serum ADA was 30.15. At this point the sensitivity was 95% and specificity was 86.7%, with a positive predictive value of 90.5%, negative predictive value of 92.9%, and accuracy of 91.4%.

### Table 9 Percentage positivity of different parameters in the diagnosis of pulmonary tuberculosis

| Parameter            | N=30 [n (%)] |
|----------------------|--------------|
| TT                   | 25 (83.3)    |
| ESR                  | 21 (70)      |
| Radiography          | 22 (73.3)    |
| Sputum AFB           | 20 (66.6)    |
| Serum ADA            | 27 (90)      |
| Toxic symptoms       | 16 (53.3)    |
| Hemoptysis           | 11 (36.3)    |

The percentage positivity of different parameters in the diagnosis of pulmonary TB. Serum ADA shows high percentage positivity (90%), followed by tuberculin skin test (83.3%), chest radiography (73.3%), ESR (70%), sputum AFB (66.6%), toxic symptoms (53.3%), and hemoptysis 36.3%.

ADA, adenosine deaminase; AFB, acid-fast bacilli; ESR, erythrocyte sedimentation rate; TT, tuberculin test.
number of lymphocytes in tuberculous pleural effusion. Therefore, the measurement of ADA level in tuberculous pleural effusion has a utility in the diagnosis of TB when other clinical and laboratory tests are negative [20] (Table 8) The best cut-off value obtained for serum ADA in the diagnosis of TB was 30.15; at this point the sensitivity was 95% and specificity was 86.7%, with a positive predictive value of 90.5%, negative predictive value of 92.2%, and accuracy of 91.4%. This result is in agreement with that of Jhamaria and colleagues, who studied serum ADA in the differential diagnosis of pulmonary TB and common nontuberculous respiratory disease. Their study included 20 healthy controls, 102 cases of pulmonary TB, 20 cases of suppurative lung diseases, and 18 cases of lung malignancy. In their study, using the cut-off point of 33 μ/l in the diagnosis of TB, sensitivity and specificity were 98 and 100%, respectively. In the same study, if 33 μ/l was taken as the cut-off point, none of the patients of nontuberculous diseases and malignancy showed value above this limit, whereas only two patients of tuberculous diseases showed values lower than 33 μ/l [21]. Lamsal and colleagues studied the diagnostic utility of ADA activity in pleural fluid and serum of tuberculous and nontuberculous respiratory disease patients. Their study included 32 cases of active pulmonary TB, 29 cases of tuberculous pleural effusion, 13 cases of nontuberculous respiratory diseases, and 32 healthy individuals as a control group. Using the cut-off point of 25 μ/l in serum in the diagnosis of TB, the sensitivity and specificity were 72.41 and 81.53%, respectively [20]. Similar results were obtained by Rao et al. [7], who used 33 μ/l as a cut-off point for serum ADA in the diagnosis of TB; the sensitivity and specificity were 98.06 and 95.35%, respectively. Agarwal et al. [16] reported high specificity and sensitivity of serum ADA in the diagnosis of smear-negative culture-positive pulmonary TB taking 33 μ/l as a cut-off point. Hassanein et al. [13] used a cut-off point of 26.2 μ/l in the diagnosis of pulmonary TB, with a sensitivity and specificity of 95 and 83.3%, respectively, with a positive predictive value of 79.2%. Chander and Shrestha [15] in their study in sputum smear-negative pulmonary TB found that, with a cut-off value of 30 μ/l, the serum ADA test showed a high specificity of 91.25% and a sensitivity of 83.10% in smear-negative pulmonary TB patients when compared with either the nontuberculous chest diseases or the healthy controls. A previous study had shown that, taking 30 μ/l as a cut-off value, the specificity and sensitivity of ADA level as a diagnostic test of pulmonary TB came to nearly 100% [22] (Table 9). The percentage positivity of different parameters in the diagnosis of pulmonary TB was determined. Serum ADA showed high percentage positivity (90%), followed by tuberculin skin test (83.3%), chest radiography (73.3%), ESR (70%), sputum for AFB (66.6%), toxic symptoms (53.3%), and hemoptysis (36.3%). These results are in accordance with those of Rao et al. [7], who studied the sensitivity of various tests in the diagnosis of pulmonary TB; serum ADA showed high percentage positivity (88%), followed by chest radiography (76%), ESR (72%), sputum for AFB (63%), and tuberculin test (61%).

Conclusion
Serum ADA level increases in patients with all forms of TB either pulmonary (smear positive and smear negative) or extrapulmonary as in tuberculous pleural effusion when compared with patients with nontuberculous lung diseases such as pneumonia, bronchiectasis, lung abscess, and lung cancer or normal individuals. Serum ADA level shows higher percentage positivity compared with clinical, radiological, and laboratory parameters in the diagnosis of pulmonary TB.

Acknowledgements
Conflicts of interest
There are no conflicts of interest.

References
1. Oxland O, Schwartzman K, Behr MA. Global tuberculosis trends: a reflection of changes in tuberculosis control or in population health? Int J Tuberc Lung Dis 2010;13:1238–1246.
2. Kent L. Improving detection of infectious diseases. Indian J Tuberc 2001;48:115–116.
3. Stead WW, Lofgren JP, Warren E, Thomas C. Tuberculosis as an endemic and nosocomial infection among the elderly in nursing homes. N Engl J Med 1988;312(23):1483–1487.
4. Raj B, Chopra RK, Lal H. Adenosine deaminase activity in pleural fluids – a diagnostic aid in tuberculous pleural effusion. Indian J Chest Dis Allied Sci 1998;42:76–80.
5. Bhargava DK, Gupta M, Nijhawan S, Dasarathy S, Kushwaha AK. Adenosine deaminase (ADA) in peritoneal tuberculosis: diagnostic value in ascitic fluid and serum. Tuberce 1990;71(2):121–126.
6. World Health Organization. WHO library cataloguing in publication data. Implementing the WHO stop TB strategy: a handbook for national tuberculosis control programs. Geneva, Switzerland: World Health Organization; 2008:17.
7. Rao KS, Kumar HA, Rudresh BM, T Srinivas, KH Bhat. A comparative study and evaluation of serum adenosine deaminase activity in the diagnosis of pulmonary tuberculosis. Biomed Res 2010;2:189–194.
8. Ganeswirer R, Chui CS, Balan S, Puthucheary SD. Comparison of BACTEC MGIT 960 system and BACTEC 460 TB system for growth and detection of Mycobacteria from clinical specimens. Malays J Pathol 2004;26(2):99–103.
9. Lardizabal AA, Reichman LB. Diagnosis of latent tuberculosis infection. Schlossberg D Tuberculosis. 5th ed. New York, NY: McGraw-Hill Press; 2006: 62–64.
10. Gusti G, Galanti B. Colorimetric method. Bergmeyer HU. Methods of enzymatic analysis. 3rd ed. Weinheim, Germany: Verlag Chemie; 1984: 315–323.
11 Mishra OP, Yusaf S, Ali Z, Nath G, Das BK. Adenosine deaminase activity and lysozyme levels in children with tuberculosis. J Tropical Pediatr 2013;46:175–178.

12 Ioanna Samarai, Petros Bakakos, D Orphanidou, P Latis, S Katsimpoula, Georgios S et al. Adenosine deaminase activity in patients with pulmonary tuberculosis and lung cancer. Adv Clin Exp Med 2007;16:533–535.

13 Hassanein K, Hosny H, Mohamed R, El-Moneim WA. Adenosine deaminase (ADA) in the diagnosis of pulmonary tuberculosis. EJB 2010;4:11–18.

14 Verma M, Narang S, Moonat A, Verma A. Study of adenosine deaminase activity in pulmonary tuberculosis and other common respiratory diseases. Indian J Clin Biochem 2004;19(1):129–131.

15 Chander A, Shrestha CD. Diagnostic value of serum adenosine deaminase levels in sputum smear negative pulmonary tuberculosis patients in Nepalese population. Asian Pac J Trop Biomed 2012;2:s1896–s1899.

16 Agarwal MK, Nath J, Mukerji PK, VML Srivastava. A study of serum adenosine deaminase activity in sputum negative patients of pulmonary tuberculosis. Indian J Tub 1991;38:139–141.

17 Conde MB, Marinho SR, Pereira-Mde F, JR Lapae-Silva, MH Saad, CL Sales et al. The usefulness of serum adenosine deaminase 2 (ADA-2) activities in adults for the diagnosis of pulmonary tuberculosis. Respir Med 2002;96:607–610.

18 Thora S, Rajsekaran P, Chhapanwal BC. Serum adenosine deaminase estimation in relation to BCG vaccination. Indian Pediatr 1995;32 (10):1087–1088.

19 Alatas F, Uslu S, Moral H, Aitas O, Metintes M, Ergenil S et al. Serum adenosine deaminase activity in pulmonary tuberculosis. Tuberk Toraks 2003;51:277–281.

20 Lamsal M, Gautam N, Bhatta N, Majhi S, Baral N, Bhattacharya SK. Diagnostic utility of adenosine deaminase (ADA) activity in pleural fluid and serum of tuberculous and non-tuberculous respiratory disease patients. Southeast Asian J Trop Med Public Health 2007;38(2):363–369.

21 Jhamaria JP, Jenaw RK, Luh SK, Madhur DK, Parihar HL, Sharma SK. Serum adenosine deaminase (ADA) in differential diagnosis of pulmonary tuberculosis and common non tubercular respiratory diseases. Ind J Tub 1988;35:25–27.

22 Gupta S, Bhatia R, Datta KR. Serodiagnosis of tuberculosis. J Commun Dis 1995;27:208–214.